| | 
・ YBRS aims to serve as a contract manufacturing organization to provide
with candidate active pharmaceutical ingredients for uses in research
and clinical investigations.
・ YBRS is committed to develop bio-technologies for production, particularly
of recombinant active pharmaceutical ingredients.
･ YBRS will join in the international campaign for the development of
bio-medical science, technology and market.
Aug.22, 2006. Establishment of Yokohama BioResearch and Supply Inc.
Apr. 10, 2007. Basic design of the main laboratory completed
Jul. 1, 2007. Start-up laboratory opened in Leading Venture Plaza,YSFP,
Yokohama
Nov. 30, 2007. The second and exapanded space for the main laboratory
secured in YSFP
Mar. 27, 2008. Basic design of the expanced main laboratory completed.
Mar. . 2008. Alliances made with Apro Life Science Institute, Inc. Tokushima,
Protein Express Inc. Chiba, and AMBiS Corp. Okinawa,
respectively for marketing, gene technology and for large
scale production.
Mar. . 2009. Construction of the main laboratory to be completed
Jun. . 2009. Operation of the main laboratory to be initiated
Capital: 36,000,000 Yen as of Dec. 5, 2007
1. Contract production of recombinant proteins from already established
recombinant micro-organisms or cultured mammalian cells. While our most
familiar organisms are recombinant E.coli and CHO cells, other organisms
will be considered.
2. Contract production of recombinant proteins from already cloned genes and
plasmids, and yet recombinant production systems to be established.
A recombinant system using E.coli suitable for industrial production is in our
hand and available.
3. Contract researches to solve specific problems in the industrial production
of candidate biopharmaceuticals.
4. Contract researches for technological R&D including those lead by the
goverment.
Representative Business Model
1. For the technological development, small scale production, and purification
of recombinant proteins for research using 5 to 90 liter jar fermentors
in a P2 or a LS2 laboratory.
2. For the preparation of microbial seed stocks and master cell banks using a
GMP controlled P2 laboratory.
3. For the production and purification of recombinant proteins suitable for
safety studies and clinical studies using 5 to 15 liter jar fermentors in a GMP
controlled P2 laboratory, or using a 300 liter jar fermentor in a GMP
controlled LS1 laboratory(in plan).
1. GMP controlling technologies and experiences with international standard for
the production of active ingredient for investigational new drugs.
2. Molecular biological technologies including cloning genes in plasmid,
formation of recombinant organisms, and facilities to pursue them.
3. Technologies of cultivation and downstream processing for high quality
recombinant proteins and facilities to pursue them.
Yasuaki KASE, Licenced pharmacist, President
After being educated in pharmacology, and having developed his carrier as a medical researcher and business manager for almost twenty years in Shionogi Pharmaceutical Co., he was invited to drive R&D projects in Nichi-Iko (pharmaceutical company), and then to steer a whole pharmaceutical company in Roman Insdutry Co. Ltd. With his rich exeprience and human relationship, he founded in 2006 and have been steering YBRS since then.
Toshiharu MATSUMURA, Ph.D. Executive Director & CRO
With backgound in biochemistry, and having enjoyed academic carrier for twenty years in Tokyo Med. and Dentl Univ., Univ. of Tokyo, Stanford Univ. and NIMR., London, he joined in Meiji Milk Products Co. Ltd. There he lead a new biopharmaceutical project from its molecular genetic studies, scale-up cultivation, and to successful GMP production. Then, he was invited to Roman Industry Co. Ltd, for the production technologies of candidate biopharmaceuticals. Currently his activity is focused mainly on YBRS project, while working concurrently in Roman Industries.
Yutaka KOHNO, Ph.D. Executive Director
With his degree in medical science, he developed his carrier as a research scientist in Fujisawa Pharmaceutical Co., and in NIDDK, NIH. After twenty four years of this scientific carrier, he was then invited to join in a venture capital specialized in life science, Bio-Frontier Pertners Inc., where he has been engaged in incubating bio-venture companies with seeds for new drugs. Currently he is extending his expertise and capabilty in new business field in bio-industries. In YRBS, he takes crucial role in co-ordinating R&D plans with business partners.
Mitsuo FUJINAMI, MA, Auditor
Being educated in Keio University Graduate School of Economy, and after having spent his first bussiness carrier in his family business, he joined in Japan Associated Finance Corporation, which was the first venture capital established in Japan. His capability in accounting business flourished since then, leading him to found a financing company by himselp. His contribution in YBRS is not only as an auditor, but is highly appreciated as a financial adviser.
Shoju KAMEYAMA,PhD. Director of Production & Research Division
With his background in biological science and technology, he initiated his carrier in Midori Juji (Green Cross), Co. Ltd, where he joined in sevelal biopharmaceutical development project including the recombinant production of human serum albumin. Through the process of company reformation towards Mitsubishi Welpharma, he continued to be in the positon of developing biopharmaceutical technologies towards the successful completion of HSA project there. In 2006, he spinned out and joined in Oxygenics Inc. for the development of artificial red cells, from where, YBRS succeeded in scouting this expert technologist as a core member.
Address: Office: Rm 233,Yokohama Bio Industry Center,
1-6 Suehiro-cho, Tsurumi-ku,
Yokohama 230-0045
Phone/Fax: +81-(0)45-511-1028 (Office)
E-mail: info@yokohamabio.co.jp
Public transportation: 15 min. Public Bus drive from Tsurumi Stn, JR Tsurumi line
Free way access: Ten min. drive from Namamugi ramp or Shioiri ramp,
Metropolitan-express way
| |
